Fig. 1.
Fig. 1. Progression-free survival for 39 evaluable patients. / The actuarial 12-month progression-free survival is 77%.

Progression-free survival for 39 evaluable patients.

The actuarial 12-month progression-free survival is 77%.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal